Physeon Reports Positive Clinical Trial Results for its Veinplicity Device
Results Confirmed that Veinplicity Dilatory Effect is 38% Greater than Commonly Used Heat Pack
Physeon GmbH, a leading developer of medical technology products for venous access, today announced positive results from its first clinical trial with Veinplicity®.
This Many healthcare professionals consider heat treatment, usually a heat pack applied to the forearm, one of the most effective ways of dilating vessels to aid intravenous cannulation. This study performed by Andrew Barton, Advanced Nurse Practitioner Vascular Access at Frimley Park Hospital in the United Kingdom, compared the dilatory effect of Veinplicity with this age-old standard. Using ultrasound to measure the mean maximum vein diameter increase, Barton found that Veinplicity dilated veins by 50% on average while heat pack dilated veins by 36%. Additionally, Veinplicity’s dilatory effect was more than two times longer than it was with heat pack.
Veinplicity is designed to alleviate one of the most common challenges in healthcare – difficult venous access. Up to 80% of hospitalized patients need a peripheral IV cannula for the infusion of fluids and medication. Although it’s the most common invasive procedure performed in hospitals, first attempt failure rates are high, and lead to increased stress for patients and staff as well as added administrative and financial burden for the hospital.
Veinplicity addresses these challenges by significantly increasing the size, rigidity and stability of forearm veins, making them easier to find and easier to cannulate first time. Veinplicity consists of a portable electronic stimulation device which passes a gentle current between electrodes placed on the palm and the bicep. It is the only technology available which has a physiological effect on veins.
“With this study we’ve confirmed that Veinplicity dilates forearm veins significantly more, and for a longer time, than commonly used heat packs” said Barton. “Other devices aid vein visualization while Veinplicity improves palpability and accessibility. It undoubtedly has an important place in the Vascular Access toolkit, as we make every effort to deliver the best possible outcome for our patients.”
Physeon’s newly named Chief Executive Officer Patrick Kullmann, an accomplished and experienced senior leader in the MedTech, BioTech and Pharmaceutical industries having served in numerous leadership positions at large, multinational companies including Johnson and Johnson (JNJ), Boston Scientific (BSX) and Medtronic (MDT), stated "We are clearly pleased with the results of this initial clinical trial indicating that our disruptive Veinplicity device has a dilatory effect which is 38% greater than the standard of care.”
The Veinplicity Device is CE Marked and is available in the EU, but is not FDA approved and is not for sale in the US.
Established in 2015 and located in Schaffhausen, Switzerland, Physeon is a boutique medical device company created to guide the development and commercialization of new innovations in healthcare. The Company embraces research and science to bring about innovative ideas and medical products that can advance the health and well-being of patients and simplify processes for healthcare professionals.
For more information, visit www.physeon.com
+1 763 516 1029
+41 78 683 2452